Index S&P 500
P/E 16.42
EPS (ttm) 8.00
Insider Own 0.67%
Shs Outstand 1.74B
Perf Week -0.66%
Market Cap 228.57B
Forward P/E 23.15
EPS next Y 5.67
Insider Trans -0.07%
Shs Float 1.73B
Perf Month 1.59%
Enterprise Value 234.99B
PEG 1.59
EPS next Q 1.30
Inst Own 80.17%
Short Float 1.03%
Perf Quarter -3.16%
Income 13.94B
P/S 5.30
EPS this Y 10.21%
Inst Trans 0.46%
Short Ratio 2.78
Perf Half Y 3.65%
Sales 43.11B
P/B 4.52
EPS next Y 10.21%
ROA 17.75%
Short Interest 17.75M
Perf YTD 16.11%
Book/sh 29.05
P/C 31.39
EPS next 5Y 10.30%
ROE 31.01%
52W High 141.23 -7.01%
Perf Year 12.63%
Cash/sh 4.18
P/FCF 33.74
EPS past 3/5Y 24.73% 29.98%
ROIC 21.95%
52W Low 110.86 18.46%
Perf 3Y 22.75%
Dividend Est. 2.39 (1.82%)
EV/EBITDA 21.94
Sales past 3/5Y -0.88% 5.63%
Gross Margin 51.83%
Volatility 2.49% 1.70%
Perf 5Y 27.70%
Dividend TTM 2.32 (1.77%)
EV/Sales 5.45
EPS Y/Y TTM 152.28%
Oper. Margin 17.56%
ATR (14) 2.49
Perf 10Y 204.92%
Dividend Ex-Date Jul 15, 2025
Quick Ratio 1.30
Sales Y/Y TTM 5.85%
Profit Margin 32.33%
RSI (14) 49.30
Recom 1.91
Dividend Gr. 3/5Y 7.17% 11.16%
Current Ratio 1.82
EPS Q/Q 38.82%
SMA20 -0.44%
Beta 0.70
Target Price 142.79
Payout 29.33%
Debt/Eq 0.27
Sales Q/Q 7.37%
SMA50 0.73%
Rel Volume 0.63
Prev Close 133.73
Employees 114000
LT Debt/Eq 0.26
Earnings Jul 17 BMO
SMA200 2.56%
Avg Volume 6.38M
Price 131.33
IPO Mar 01, 1937
Option/Short Yes / Yes
EPS/Sales Surpr. 0.33% 0.45%
Trades
Volume 4,050,918
Change -1.79%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-18-25 Upgrade
Jefferies
Hold → Buy
$145
Jun-16-25 Initiated
Leerink Partners
Market Perform
$143
Oct-08-24 Initiated
Oppenheimer
Outperform
$130
Sep-19-24 Initiated
Piper Sandler
Overweight
$131
Jul-30-24 Downgrade
Edward Jones
Buy → Hold
May-30-24 Initiated
Goldman
Buy
$121
Jul-21-23 Upgrade
Wolfe Research
Underperform → Peer Perform
May-30-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$112
Apr-20-23 Reiterated
Wolfe Research
Underperform
$107 → $103
Apr-20-23 Reiterated
UBS
Buy
$117 → $130
Apr-20-23 Reiterated
Raymond James
Outperform
$116 → $123
Apr-20-23 Reiterated
JP Morgan
Overweight
$118 → $122
Apr-20-23 Reiterated
Bernstein
Outperform
$132 → $133
Apr-20-23 Reiterated
Barclays
Overweight
$125 → $127
Mar-29-23 Initiated
UBS
Buy
$117
Oct-26-22 Initiated
Mizuho
Neutral
$105
Oct-18-22 Initiated
Barclays
Overweight
$118
Oct-12-22 Initiated
Jefferies
Hold
$110
Jul-06-22 Initiated
Wolfe Research
Underperform
$95
Mar-02-22 Resumed
BofA Securities
Buy
$140
Show Previous Ratings
Sep-13-25 06:42AM
Sep-11-25 06:48PM
Sep-10-25 05:50PM
11:40AM
Sep-09-25 09:05AM
04:51PM
Loading…
Sep-08-25 04:51PM
Sep-07-25 02:37PM
Sep-05-25 08:50AM
Sep-04-25 08:47AM
04:09AM
Sep-03-25 07:00AM
05:55AM
Sep-02-25 04:25PM
11:06AM
Sep-01-25 12:11PM
09:54AM
Loading…
09:54AM
09:54AM
Aug-31-25 01:36PM
Aug-29-25 09:48AM
08:00AM
Aug-28-25 12:01AM
Aug-27-25 12:50PM
12:38PM
08:55AM
08:40AM
Aug-26-25 05:13AM
Aug-25-25 11:40AM
08:49AM
Aug-23-25 06:45AM
Aug-22-25 11:30AM
06:07AM
Loading…
Aug-21-25 06:07AM
Aug-20-25 08:40PM
11:20AM
11:20AM
09:30AM
Aug-19-25 09:00AM
Aug-18-25 09:00AM
08:50AM
Aug-15-25 10:00AM
12:40AM
Aug-14-25 09:50AM
08:33AM
Aug-13-25 10:11AM
09:21AM
08:37AM
Aug-12-25 05:37AM
05:32AM
04:49AM
04:42AM
Aug-11-25 12:07PM
10:02AM
08:48AM
Aug-09-25 06:45AM
Aug-08-25 09:39AM
08:43AM
07:56AM
Aug-07-25 11:40AM
10:16AM
Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma
(GlobeNewswire)
05:39AM
Aug-06-25 04:05PM
04:05PM
09:00AM
07:41AM
Aug-05-25 11:32PM
Aug-01-25 08:15AM
Jul-31-25 03:26PM
12:23AM
Jul-30-25 05:08AM
Jul-29-25 01:43PM
10:02AM
04:38AM
04:31AM
04:02AM
Jul-28-25 08:09AM
02:08AM
01:42AM
Jul-27-25 03:00PM
Jul-25-25 11:50PM
07:00PM
01:11PM
11:13AM
05:27AM
Jul-24-25 09:38AM
09:06AM
05:00AM
Jul-23-25 05:06PM
10:54AM
09:00AM
04:30AM
[Latest] Global Inferior Vena Cava IVC Filter Market Size/Share Worth USD 2,094.10 Million by 2034 at a 8.88% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
(GlobeNewswire)
Jul-22-25 01:30PM
11:40AM
08:32AM
08:30AM
Jul-21-25 12:30PM
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
(GlobeNewswire)
08:43AM
06:13AM
06:02AM
05:22AM
05:20AM
Jul-20-25 12:15AM
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boudreau Philip P EVP AND CFO Aug 08 '25 Sale 134.55 5,550 746,758 51,003 Aug 11 05:53 PM Boudreau Philip P Officer Aug 08 '25 Proposed Sale 134.55 5,550 746,758 Aug 08 06:30 PM Blount Sally E. Director Apr 30 '25 Sale 129.66 2,600 337,116 34,058 May 02 05:04 PM SALLY E BLOUNT Director Apr 30 '25 Proposed Sale 129.66 2,600 337,116 Apr 30 04:23 PM Earnhardt Lisa D EVP AND GROUP PRESIDENT Mar 06 '25 Option Exercise 80.98 91,167 7,382,704 163,095 Mar 07 06:55 PM Earnhardt Lisa D EVP AND GROUP PRESIDENT Mar 07 '25 Option Exercise 80.98 200 16,196 72,128 Mar 07 06:55 PM Earnhardt Lisa D EVP AND GROUP PRESIDENT Mar 06 '25 Sale 133.82 91,167 12,199,968 71,928 Mar 07 06:55 PM Earnhardt Lisa D EVP AND GROUP PRESIDENT Mar 07 '25 Sale 136.65 200 27,329 71,928 Mar 07 06:55 PM Lisa D. Earnhardt Officer Mar 07 '25 Proposed Sale 136.65 200 27,329 Mar 07 06:28 PM Lisa D. Earnhardt Officer Mar 06 '25 Proposed Sale 133.82 91,167 12,199,967 Mar 06 05:47 PM Wainer Andrea F RETIRED EVP Mar 03 '25 Sale 138.17 949 131,123 74,381 Mar 04 08:05 PM Shroff Eric Senior Vice President Mar 03 '25 Sale 138.17 562 77,652 31,970 Mar 04 08:00 PM Morrone Louis H. EXECUTIVE VICE PRESIDENT Mar 03 '25 Sale 138.17 1,111 153,507 66,878 Mar 04 07:49 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Mar 03 '25 Sale 138.17 791 109,292 95,583 Mar 04 07:44 PM MCCOY JOHN A. JR. VICE PRESIDENT AND CONTROLLER Mar 03 '25 Sale 138.17 562 77,652 21,061 Mar 04 07:39 PM Eric Shroff Officer Mar 03 '25 Proposed Sale 138.17 562 77,651 Mar 03 08:40 PM Andrea F. Wainer Retired Officer Mar 03 '25 Proposed Sale 138.17 949 131,123 Mar 03 08:18 PM Louis H. Morrone Officer Mar 03 '25 Proposed Sale 138.17 1,111 153,506 Mar 03 08:08 PM Mary K. Moreland Officer Mar 03 '25 Proposed Sale 138.17 791 109,292 Mar 03 07:58 PM John A. McCoy, Jr. Officer Mar 03 '25 Proposed Sale 138.17 562 77,651 Mar 03 07:52 PM Ford Robert B CHAIRMAN AND CEO Feb 05 '25 Option Exercise 38.40 285,388 10,958,899 505,447 Feb 07 05:51 PM Ford Robert B CHAIRMAN AND CEO Feb 05 '25 Sale 131.17 285,388 37,435,200 220,059 Feb 07 05:51 PM Robert B. Ford Officer Feb 05 '25 Proposed Sale 131.17 285,388 37,435,238 Feb 05 06:52 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Jan 29 '25 Option Exercise 38.40 131,360 5,044,224 316,166 Jan 31 07:16 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Jan 30 '25 Option Exercise 38.40 58,428 2,243,635 243,234 Jan 31 07:16 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Jan 29 '25 Sale 128.35 131,360 16,859,675 184,806 Jan 31 07:16 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Jan 30 '25 Sale 128.07 58,428 7,482,629 184,806 Jan 31 07:16 PM Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT Jan 30 '25 Option Exercise 38.40 23,771 912,806 149,468 Jan 31 07:08 PM Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT Jan 30 '25 Sale 128.50 23,771 3,054,574 125,697 Jan 31 07:08 PM Morrone Louis H. EXECUTIVE VICE PRESIDENT Jan 28 '25 Sale 127.39 2,644 336,819 0 Jan 30 07:33 PM Hubert L. Allen Officer Jan 30 '25 Proposed Sale 128.07 58,428 7,482,628 Jan 30 05:33 PM Daniel Gesua Sive Salvadori Officer Jan 30 '25 Proposed Sale 128.50 23,771 3,054,573 Jan 30 05:26 PM Hubert L. Allen Officer Jan 29 '25 Proposed Sale 128.35 131,360 16,859,675 Jan 29 05:30 PM Funck, Jr. Robert E. Officer Nov 04 '24 Proposed Sale 120.00 15,000 1,800,000 Nov 04 04:02 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Oct 21 '24 Option Exercise 47.00 157,421 7,398,787 342,227 Oct 23 05:10 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Oct 21 '24 Sale 117.04 157,421 18,424,298 184,806 Oct 23 05:10 PM ALLEN HUBERT L Officer Oct 21 '24 Proposed Sale 118.89 157,421 18,715,783 Oct 21 04:08 PM